ETFs H. Lundbeck A/S

HLUN B

DK0061804770

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 09:50:00 05/12/2025 pm IST			5-day change	1st Jan Change
44.78 ^DKK	+0.63%		+0.81%	+8.37%

03/12	BNP Paribas Exane Raises Price Target for Lundbeck to 45 Danish Kroner, Reiterates Neutral Rating - BN	FW
02/12	H. Lundbeck A/S Presents Comprehensive New Bexicaserin Dataset Epilepsies	CI

ETFs positioned on H. Lundbeck A/S

Name	Weight	AuM	Varia. Jan 1.	Investor
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD	0.25%	4 M€	+20.34%	-
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	0%	33,076 M€	+20.06%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0%	839 M€	+7.14%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	62 M€	+6.61%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0%	619 M€	+6.89%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	83 M€	+5.57%	-
CI MARRET ALTERNATIVE ABSOLUTE RETURN BOND ETF - CAD	-0%	17 M€	0.00%	-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâs disease, Bipolar disorder, depression, epilepsy, Huntingtonâs disease, Parkinsonâs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâs disease, Azilect for the treatment of Parkinsonâs disease, Xenazine for the treatment of Huntingtonâs disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Employees

5,700

Sector

Pharmaceuticals

Calendar

07/12/2025 - American Epilepsy Society Meeting - Nuggehally R. Srinivas

More about the company